Hepatitis C Information - Human Genome Sciences Reports Positive Interim Results of Phase 2 ...

Human Genome Sciences Reports Positive Interim Results of Phase 2 ...
Yahoo! News (press release) - Mar 14, 2006... safety, tolerability and efficacy of Albuferon(TM) (albumin-interferon alpha 2b) in combination with ribavirin in patients with chronic hepatitis C who failed ...

ViRexx Announces Collaboration with Defence Research and ...
CCNMatthews (press release), Canada - Mar 31, 2006... The Company is also conducting preclinical studies on Chimigen TM therapeutic vaccine candidates to treat chronic hepatitis C infections. ...

Chinese Patients With Chronic Hepatitis B Respond Better To ...
Medical News Today (press release), UK - Mar 27, 2006... of other product candidates in Idenix's portfolio, including valopicitabine (NM283), a direct antiviral for the treatment of chronic hepatitis C. ...

Preclinical Studies Presented at AACR Meeting Show Potential of ...
PharmaLive.com (press release), PA - Apr 3, 2006... In February Peregrine successfully completed enrollment in a Tarvacin Phase l clinical trial for the treatment of chronic hepatitis C virus infection ...

- Interim 12-Week Data Suggest At Least Comparable Antiviral ...
PR Newswire (press release), NY - Mar 14, 2006... the efficacy and safety of Albuferon(TM) (albumin-interferon alpha 2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C who are ...